VELPANAT 500 MG TAB. BOT.

About

Velpanat, a combination of sofosbuvir and velpatasvir, is a direct-acting antiviral (DAA) medication used for the treatment of chronic hepatitis C virus (HCV) infection across all genotypes (pan-genotypic). Sofosbuvir is a nucleotide analog NS5B polymerase inhibitor, while velpatasvir is an NS5A inhibitor. This synergistic action effectively blocks different stages of the viral life cycle, leading to high sustained virologic response rates, often exceeding 95%. It is indicated for patients with or without cirrhosis, and in some cases, in combination with ribavirin for decompensated cirrhosis, offering a comprehensive treatment option. The treatment duration is typically 12 weeks, providing a highly effective and convenient regimen that has revolutionized HCV therapy by offering a cure for many patients.

Uses

• Chronic hepatitis C virus (HCV) infection.
• Pan-genotypic HCV treatment.
• HCV with compensated cirrhosis.
• HCV with decompensated cirrhosis (with ribavirin).

Directions For Use

Take one tablet orally once daily with or without food.

Benefits

• High sustained virologic response (SVR) rates.
• Effective across all HCV genotypes.
• Convenient once-daily dosing.
• Well-tolerated with minimal side effects.
• Suitable for patients with cirrhosis.
• Short treatment duration (typically 12 weeks).

Side Effects

• Headache
• Fatigue
• Nausea
• Diarrhea
• Insomnia
• Anemia (if with ribavirin)
• Rash
• Irritability
• Dizziness
• Bradycardia (with amiodarone)
• Elevated bilirubin (rare)
• Pancreatitis (rare)

Safety Measures

• Alcohol - Avoid or limit alcohol consumption as it can worsen liver disease and interfere with treatment.
• Pregnancy - Not recommended; use only if the potential benefit justifies the potential risk to the fetus.
• Breastfeeding - Not recommended due to potential for serious adverse effects in the infant.
• Liver - Use with caution in decompensated cirrhosis; monitor closely for liver function.
• Kidney - No dosage adjustment needed for mild to severe renal impairment, but not studied in ESRD on dialysis.
• Lung - No specific contraindication; generally safe for use in patients with lung conditions.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.